Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 6:18:9-11.
doi: 10.1016/j.xjon.2023.12.011. eCollection 2024 Apr.

Incidence and impact of hypoattenuated leaflet thickening following aortic valve replacement using a glycerol-preserved bioprosthesis

Bastien Poitier  1 , Pierre Dahdah  1 , Margaux Bernardini  1 , Lucas Coroyer  1 , Mohamed Nouar  1 , Ramzi Abi Akar  1 , Alain Bel  1 , David M Smadja  2 , Leonora Du Puy-Montbrun  1 , Paul Achouh  1
Affiliations

Incidence and impact of hypoattenuated leaflet thickening following aortic valve replacement using a glycerol-preserved bioprosthesis

Bastien Poitier et al. JTCVS Open. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

Figures

None
HALT visualized through CT-scan imaging on an INSPIRIS bioprosthesis at the 3-month mark.
Figure 1
Figure 1
A, HALT occurrence according to antithrombotic treatment. B, Mean aortic gradient in HALT and no-HALT patients. The lower and upper borders of the box represent the lower and upper quartiles (25th percentile and 75th percentile). The middle horizontal line represents the median. The lower and upper whiskers represent the minimum and maximum values. HALT, Hypoattenuating leaflet thickening.
See this image and copyright information in PMC

References

    1. Bavaria J.E., Griffith B., Heimansohn D.A., Rozanski J., Johnston D.R., Bartus K., et al. Five-year outcomes of the COMMENCE trial investigating aortic valve replacement with RESILIA tissue. Ann Thorac Surg. 2023;115:1429–1436. doi: 10.1016/j.athoracsur.2021.12.058. - DOI - PubMed
    1. Makkar R.R., Blanke P., Leipsic J., Thourani V., Chakravarty T., Brown D., et al. Subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic valves: PARTNER 3 cardiac computed tomography substudy. J Am Coll Cardiol. 2020;75:3003–3015. doi: 10.1016/j.jacc.2020.04.043. - DOI - PubMed
    1. Blanke P., Leipsic J.A., Popma J.J., Yakubov S.J., Deeb G.M., Gada H., et al. Bioprosthetic aortic valve leaflet thickening in the Evolut low risk sub-study. J Am Coll Cardiol. 2020;75:2430–2442. doi: 10.1016/j.jacc.2020.03.022. - DOI - PubMed
    1. Poitier B., Rancic J., Richez U., Piquet J., El Batti S., Smadja D.M. Fibrin deposition on bovine pericardium tissue used for bioprosthetic heart valve drives its calcification. Front Cardiovasc Med. 2023;10 doi: 10.3389/fcvm.2023.1198020. - DOI - PMC - PubMed
    1. Dangas G.D., Tijssen J.G.P., Wöhrle J., Søndergaard L., Gilard M., Möllmann H., et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med. 2020;382:120–129. doi: 10.1056/NEJMoa1911425. - DOI - PubMed

LinkOut - more resources